Key terms
About RVNC
Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RVNC news
Yesterday
5:59am ET
Barclays Sticks to Their Buy Rating for Revance Therapeutics (RVNC)
Mar 04
9:33am ET
Revance 16M share Spot Secondary priced at $6.25
Mar 04
6:41am ET
Revance announces $100M offering of common stock
Mar 01
8:15am ET
Revance price target raised to $16 from $15 at Guggenheim
Feb 29
5:19pm ET
Revance price target raised to $9 from $8 at Goldman Sachs
Feb 29
11:01am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Revance Therapeutics (RVNC), VYNE Therapeutics (VYNE) and Ironwood Pharma (IRWD)
Feb 29
8:17am ET
Revance Therapeutics (RVNC) Gets a Buy from Stifel Nicolaus
Feb 29
7:48am ET
Revance Therapeutics (RVNC) Receives a Buy from Piper Sandler
Feb 29
7:43am ET
Revance price target lowered to $20 from $42 at Piper Sandler
Feb 29
7:11am ET
Analysts Are Bullish on These Healthcare Stocks: Avidity Biosciences (RNA), Revance Therapeutics (RVNC)
Feb 29
6:40am ET
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)
Feb 29
2:45am ET
Revance Therapeutics (RVNC) Gets a Buy from Barclays
Feb 28
6:45pm ET
Revance Therapeutics: Strategic Pivot and Growth Potential Justify Buy Rating
Feb 28
4:23pm ET
Revance Therapeutics Renews Manufacturing Deal and Announces Executive Transition
Feb 28
4:15pm ET
Revance sees FY24 product revenue at least $280M
Feb 28
4:15pm ET
Revance reports Q4 EPS (62c), consensus (72c)
Feb 23
7:45am ET
Revance price target lowered to $12 from $15 at H.C. Wainwright
Feb 23
3:05am ET
Barclays Remains a Buy on Revance Therapeutics (RVNC)
Feb 13
4:46pm ET
Revance Therapeutics Sets 2024 Goals, Updates Executive Severance Plan
Feb 07
4:45am ET
Revance Therapeutics Sets Executive Compensation for 2024
Feb 02
8:09am ET
Revance announces CMS assigns permanent J-code for Daxxify
Jan 29
5:07am ET
Barclays Keeps Their Buy Rating on Revance Therapeutics (RVNC)
No recent press releases are available for RVNC
RVNC Financials
Key terms
Ad Feedback
RVNC Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RVNC Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
